compound introduction
PF-03463275 is a centrally penetrant, orally available, selective, and competitive GlyT1 (glycine transporter-1) reversible inhibitor, with a K i of 11.6 nM. PF-03463275 has the potential for Schizophrenia research. In Vivo PF-03463275 (1-10 mg/kg; s.c.) attenuates oscillatory potentials (OPs). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Sprague-Dawley ratsDosage: 1, 3 and 10 mg/kg Administration: S.c. Result: A dose-dependent reduction in the amplitude of oscillatory potentials (OPs) elicited from the dark-adapted rats.
